molybdenum has been researched along with Alzheimer Disease in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 7 (38.89) | 2.80 |
| Authors | Studies |
|---|---|
| Araújo, SES; Cardoso, SA; Cerchiaro, G; Coelho, FC; Coelho, GF; Daher, JPL; Guimarães, AG | 1 |
| Botchway, BOA; Fang, M; Liu, X; Zhou, Y | 1 |
| Amin, ND; Balijepalli, A; Bruce, RC; Cardone, A; Guros, NB; Klauda, JB; Le, ST; Pant, HC; Richter, CA; Zhang, S | 1 |
| Abohamza, E; Berry, T; Moustafa, AA | 1 |
| Hu, X; Li, D; Ren, C; Zhou, Q | 1 |
| Ambi, A; Hatfield, J; Miller, LM; Sullivan, JK; Van Nostrand, WE; Victor, TW; Xu, F; Zhu, X | 1 |
| Jang, J; Park, CB | 1 |
| Andrikopoulos, N; Davis, TP; Ding, F; Kakinen, A; Ke, PC; Kwak, E; Leong, DT; Li, Y; Nandakumar, A; Sun, Y; Tang, H; Wang, D; Zhu, H | 1 |
| Cai, S; Han, Q; Qi, C; Wang, C; Wang, X; Yang, L; Yang, R | 1 |
| Chen, GR; Dou, WT; Guo, Z; He, XP; Li, Q; Zhang, HY; Zhang, JJ; Zhu, W | 1 |
| Guo, S; Hua, X; Xu, W; Yuan, R; Zheng, T; Zhou, X | 1 |
| Gao, N; Liu, X; Ma, M; Qu, X; Ren, J; Sun, Y; Wang, Y | 1 |
| Chen, Q; Liu, J; Yang, L; Zhang, J; Zheng, C; Zheng, W; Zhou, Y | 1 |
| Gao, N; Guan, Y; Qu, X; Ren, J | 1 |
| Brewer, GJ | 1 |
| Brewer, G; Cobb, KE; Domes, C; Harris, CJ; Quinn, JF; Ralle, M; Wadsworth, TL | 1 |
| Suttle, NF | 1 |
| Harrington, CR | 1 |
5 review(s) available for molybdenum and Alzheimer Disease
| Article | Year |
|---|---|
Is There a Connection between the Metabolism of Copper, Sulfur, and Molybdenum in Alzheimer's Disease? New Insights on Disease Etiology.
Topics: Alzheimer Disease; Copper; Diet; Humans; Molybdenum; Sulfur | 2022 |
Biometals in Alzheimer disease: emerging therapeutic and diagnostic potential of molybdenum and iodine.
Topics: Alzheimer Disease; Copper; Humans; Iodine; Molybdenum; Trace Elements; Zinc | 2023 |
A disease-modifying treatment for Alzheimer's disease: focus on the trans-sulfuration pathway.
Topics: Alzheimer Disease; Animals; Homocysteine; Humans; Molybdenum; Neuroprotective Agents; Selenocysteine | 2020 |
The risks of free copper in the body and the development of useful anticopper drugs.
Topics: Alzheimer Disease; Angiogenesis Inhibitors; Autoimmunity; Copper; Fibrosis; Hepatolenticular Degeneration; Humans; Inflammation; Molybdenum; Neurodegenerative Diseases; Penicillamine; Trientine | 2008 |
Copper imbalances in ruminants and humans: unexpected common ground.
Topics: Alzheimer Disease; Animals; Chelating Agents; Copper; Deficiency Diseases; Enzyme Inhibitors; Hepatolenticular Degeneration; Humans; Infections; Inflammation; Molybdenum; Neoplasms; Nutritional Requirements; Ruminants | 2012 |
13 other study(ies) available for molybdenum and Alzheimer Disease
| Article | Year |
|---|---|
Quantum capacitance-limited MoS
Topics: Alzheimer Disease; Biosensing Techniques; Cyclin-Dependent Kinase 5; Disulfides; Electric Capacitance; Humans; Hydrogen-Ion Concentration; Ionic Liquids; Kinetics; Limit of Detection; Molybdenum; Signal-To-Noise Ratio; Temperature; Transistors, Electronic | 2019 |
Mitochondria-targeted TPP-MoS
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Mice; Microglia; Mitochondria; Molybdenum; Neuroprotection | 2020 |
Copper accumulation and the effect of chelation treatment on cerebral amyloid angiopathy compared to parenchymal amyloid plaques.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cerebral Amyloid Angiopathy; Chelating Agents; Copper; Disease Models, Animal; Humans; Mice, Transgenic; Microscopy, Fluorescence; Molybdenum; Parenchymal Tissue; Plaque, Amyloid | 2020 |
Near-Infrared-Active Copper Molybdenum Sulfide Nanocubes for Phonon-Mediated Clearance of Alzheimer's β-Amyloid Aggregates.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Copper; Hydrogen Bonding; Infrared Rays; Mice; Molybdenum; Nanostructures; Protein Aggregates | 2021 |
Ultrasmall Molybdenum Disulfide Quantum Dots Cage Alzheimer's Amyloid Beta to Restore Membrane Fluidity.
Topics: 2-Naphthylamine; Actins; Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Cell Membrane; Disulfides; Humans; Hydrophobic and Hydrophilic Interactions; Laurates; Membrane Fluidity; Microscopy, Confocal; Molecular Dynamics Simulation; Molybdenum; Nanomedicine; Quantum Dots | 2021 |
Molybdenum Disulfide Nanoparticles as Multifunctional Inhibitors against Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Disulfides; Humans; Molybdenum; Nanoparticles; Peptide Fragments | 2017 |
Fluorescence Imaging of Alzheimer's Disease with a Flat Ensemble Formed between a Quinoline-Malononitrile AIEgen and Thin-Layer Molybdenum Disulfide.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Disulfides; Fluorescent Dyes; Limit of Detection; Male; Mice, Inbred ICR; Mice, Transgenic; Molybdenum; Optical Imaging; Peptide Fragments; Quinolines | 2019 |
Determination of Alzheimer biomarker DNA by using an electrode modified with in-situ precipitated molybdophosphate catalyzed by alkaline phosphatase-encapsulated DNA hydrogel and target recycling amplification.
Topics: Alkaline Phosphatase; Alzheimer Disease; Biomarkers; Catalysis; DNA; Electrochemical Techniques; Electrodes; Humans; Hydrogels; Molybdenum; Phosphoric Acids | 2019 |
A Near-Infrared-Controllable Artificial Metalloprotease Used for Degrading Amyloid-β Monomers and Aggregates.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Disulfides; Humans; Metalloproteases; Molybdenum; Spectrophotometry, Infrared | 2019 |
Mo polyoxometalate nanoclusters capable of inhibiting the aggregation of Aβ-peptide associated with Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Humans; Materials Testing; Metal Nanoparticles; Molybdenum; Multiprotein Complexes; Nanocomposites; Peptide Fragments; Tungsten Compounds | 2014 |
Rationally Designed CeNP@MnMoS4 Core-Shell Nanoparticles for Modulating Multiple Facets of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cerium; Copper; Humans; Manganese; Metal Nanoparticles; Molybdenum; Neurites; Oxidative Stress; Particle Size; Protein Aggregates; Sulfides; Surface Properties | 2016 |
A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Animals; Blotting, Western; Cerebral Cortex; Ceruloplasmin; Chelating Agents; Copper; Enzyme-Linked Immunosorbent Assay; Hippocampus; Immunohistochemistry; Maze Learning; Memory Disorders; Mice; Mice, Transgenic; Molybdenum; Random Allocation | 2010 |
Lowry protein assay containing sodium dodecyl sulfate in microtiter plates for protein determinations on fractions from brain tissue.
Topics: Alzheimer Disease; Brain Chemistry; Humans; Indicators and Reagents; Microchemistry; Molybdenum; Nerve Tissue Proteins; Sodium Dodecyl Sulfate; Spectrophotometry; Tungsten; Tungsten Compounds | 1990 |